The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and molecular characteristics of patients with AML with an exceptional response to ivosidenib.
 
Justin M. Watts
Consulting or Advisory Role - Celgene; Jazz Pharmaceuticals; Pfizer
Speakers' Bureau - Jazz Pharmaceuticals
Research Funding - Takeda
 
Prapti Arvind Patel
Employment - SERVIER
Honoraria - Jazz Pharmaceuticals
 
Sung Choe
Employment - Agios; SERVIER
Stock and Other Ownership Interests - Agios
Patents, Royalties, Other Intellectual Property - Patents derived from my work at Agios
Travel, Accommodations, Expenses - Agios
 
Xiaofei Bai
Employment - SERVIER
 
Dylan M. Marchione
Employment - SERVIER
 
Eytan M. Stein
Stock and Other Ownership Interests - Auron Therapeutics
Consulting or Advisory Role - Abbvie; Agios; Aptose Biosciences; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Calithera Biosciences; CTI BioPharma Corp; Daiichi Sankyo Pharmaceutical; Debiopharm Group; Foghorn Therapeutics; GEMoaB; Genentech; Genesis Pharma; Gilead Sciences; ImmunoGen; Janssen; Jazz Pharmaceuticals; Jnana Therapeutics; Menarini; Neoleukin Therapeutics; Novartis; Oncusp Therapeutics; Ono Pharmaceutical; Pinot Bio; SERVIER; Syndax
Research Funding - Agios (Inst); Bayer (Inst); BioTheryX (Inst); Bristol-Myers Squibb/Celgene (Inst); Cleave Biosciences (Inst); Eisai (Inst); Foghorn Therapeutics (Inst); Gilead Sciences (Inst); Loxo/Lilly (Inst); Prelude Therapeutics (Inst); SERVIER (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst)